MARKET

SYN

SYN

SYNTHETIC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.5045
+0.0025
+0.50%
After Hours: 0.5013 -0.0032 -0.63% 18:23 05/17 EDT
OPEN
0.4939
PREV CLOSE
0.5020
HIGH
0.5088
LOW
0.4882
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
1.700
52 WEEK LOW
0.2610
MARKET CAP
66.62M
P/E (TTM)
-0.8512
1D
5D
1M
3M
1Y
5Y
26 Stocks Moving in Wednesday's Pre-Market Session
Gainers Biomerica, Inc. (NASDAQ: BMRA) shares rose 30.8% to $4.46 in pre-market trading. Biomerica recently said its COVID-19 antigen rapid test can be performed with a nasal swab.
Benzinga · 5d ago
Human Microbiome Market Size,Growth, Share Global Trend, Industry News, Industry Demand, Business Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2024
May 10, 2021 (The Expresswire) -- Global Human Microbiome Market Research Report study covers the global and regional market with an in-depth analysis of the...
The Express Wire · 05/10 07:36
Maxim Group Initiates a Buy Rating on Synthetic Biologics (SYN)
In a report released yesterday, Jason McCarthy from Maxim Group initiated coverage with a Buy rating on Synthetic Biologics (SYN) and a price target of
SmarterAnalyst · 05/07 13:35
Irritable Bowel Syndrome Drugs Market Growth to Witness a Surge by Rise in Prevalence of the Disease with a Notable CAGR during 2020 - 2029
May 07, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Irritable Bowel Syndrome Drugs Market: Global Demand Analysis & Opportunity...
AmericaNewsHour · 05/07 13:33
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume.
Benzinga · 05/07 09:10
Amyotrophic Lateral Sclerosis Market by Product Type, by End-User, Application, by Region - Forecast 2021 - 2028 By Ameco Research
pune, India, Fri, 07 May 2021 03:42:09 / Comserve Inc. / -- Amyotrophic Lateral Sclerosis Market Research Report 2021 provides an actual industry viewpoint,...
Comserve · 05/07 07:44
Global Human Microbiome Market – Major Players are Enterome, Rebiotix Inc., Yakult Honsha Co., Ltd., Osel Inc
May 06, 2021 (Heraldkeepers) -- The Global Human Microbiome Market is anticipated to show at a CAGR 23.52% over the forecast period. A recent report found on...
Heraldkeepers · 05/06 13:14
8-K: Synthetic Biologics, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/05 21:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYN. Analyze the recent business situations of SYNTHETIC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYN stock price target is 1.875 with a high estimate of 2.500 and a low estimate of 1.250.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 1.75M
% Owned: 1.32%
Shares Outstanding: 132.04M
TypeInstitutionsShares
Increased
3
253.42K
New
2
98.10K
Decreased
6
47.38K
Sold Out
5
523.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Kraws
Chief Executive Officer/Chief Financial Officer/Director
Steven Shallcross
Director
John Monahan
Independent Director
Jeffrey Wolf
No Data
  • All
  • Financials
  • Insiders
More
About SYN
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Webull offers kinds of Synthetic Biologics Inc stock information, including AMEX:SYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYN stock methods without spending real money on the virtual paper trading platform.